Resources

Customized solutions for biologics development: leveraging adaptive platforms to meet customer needs

Customized solutions for biologics development: leveraging adaptive platforms to meet customer needs

The rapidly growing numbers of monoclonal antibodies (mAbs), fusion proteins and biosimilars produced by the pharma industry have greatly improved patient care and resulted in a proliferation of innovative treatment options. To date, there are over 100 biosimilars [1, 2], 162 mAbs [3] and over 11 fusion proteins [4] approved for therapeutic use. These new therapeutic proteins are often more...

read more
Skip to content